Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 10/2012

01-10-2012 | Special Article

Guidelines for biomarker testing in colorectal carcinoma (CRC): a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM)

Authors: Pilar García-Alfonso, Ramón Salazar, Jesús García-Foncillas, Eva Musulén, Rocío García-Carbonero, Artemio Payá, Pedro Pérez-Segura, Santiago Ramón y Cajal, Samuel Navarro

Published in: Clinical and Translational Oncology | Issue 10/2012

Login to get access

Abstract

This consensus statement, conceived as a joint initiative of the Spanish Society of Pathology and the Spanish Society of Medical Oncology, makes diagnostic and treatment recommendations for the management of patients with hereditary, localised and advanced CRC based on the current scientific evidence on biomarker use. This consensus statement thus provides an opportunity to improve healthcare efficiency and resource use, which will benefit these patients. Based on the currently available data on this subject, this expert group recommends testing for microsatellite instability (MSI) in patients with localised CRC, as this is a strong predictive factor for deciding on adjuvant treatment. However, although the ColoPrint® and Oncotype Dx® gene expression signatures have been shown to have prognostic value, no consensus yet exists concerning their use in clinical practice. For advanced CRC, it is essential to test for KRAS mutation status before administering an anti-EGFR treatment, such as cetuximab or panitumumab. However, testing for other biomarkers, such as BRAF, EGFR, PI3K and PTEN mutations, should not be done routinely, because this does not influence treatment planning at the present time. Other important issues addressed include organisational requirements and the quality controls needed for proper testing of these biomarkers as well as the legal implications to be borne in mind when testing some biomarkers.
Literature
1.
American Gastroenterological Association (2001) American Gastroenterological Association medical position statement: hereditary colorectal cancer and genetic testing. Gastroenterology 121:195–197
2.
Vasen HF, Watson P, Mecklin JP et al (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 116:1453–1456PubMedCrossRef
3.
4.
Umar A, Boland CR, Terdiman JP et al (2004) Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96:261–268PubMedCrossRef
5.
Balmana J, Stockwell DH, Steyerberg EW et al (2006) Prediction of MLH1 and MSH2 mutations in Lynch syndrome. JAMA 296:1469–1478PubMedCrossRef
6.
Popat S, Houlston RS (2005) A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. Eur J Cancer 41:2060–2070PubMedCrossRef
7.
Shibata D, Reale MA, Lavin P et al (1996) The DCC protein and prognosis in colorectal cancer. N Engl J Med 335:1727–1732PubMedCrossRef
8.
Alazzouzi H, Alhopuro P, Salovaara R et al (2005) SMAD4 as a prognostic marker in colorectal cancer. Clin Cancer Res 11:2606–2611PubMedCrossRef
9.
Roth AD, Tejpar S, Yan P et al (2009) Stage-specific prognostic value of molecular markers in colon cancer: results of the translational study on the PETACC 3–EORTC 40993–SAKK 60-00 trial. ASCO Meeting Abstracts 27:4002
10.
Ogino S, Nosho K, Kirkner GJ et al (2009) PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol 27:1477–1484PubMedCrossRef
11.
Popat S, Hubner R, Houlston RS (2005) Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 23:609–618PubMedCrossRef
12.
Sargent DJ, Marsoni S, Monges G et al (2010) Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 28:3219–3226PubMedCrossRef
13.
Hutchins G, Southward K, Handley K et al (2011) Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 29:1261–1270PubMedCrossRef
14.
Sinicrope FA, Foster NR, Thibodeau SN et al (2011) DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst 103:863–875PubMedCrossRef
15.
Tejpar S, Saridaki Z, Delorenzi M et al (2011) Microsatellite instability, prognosis and drug sensitivity of stage II and III colorectal cancer: more complexity to the puzzle. J Natl Cancer Inst 103:841–844PubMedCrossRef
16.
Bertucci F, Salas S, Eysteries S et al (2004) Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene 23:1377–1391PubMedCrossRef
17.
Wang Y, Jatkoe T, Zhang Y et al (2004) Gene expression profiles and molecular markers to predict recurrence of Dukes’ B colon cancer. J Clin Oncol 22:1564–1571PubMedCrossRef
18.
Komuro K, Tada M, Tamoto E et al (2005) Right- and left-sided colorectal cancers display distinct expression profiles and the anatomical stratification allows a high accuracy prediction of lymph node metastasis. J Surg Res 124:216–224PubMedCrossRef
19.
Eschrich S, Yang I, Bloom G et al (2005) Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol 23:3526–3535PubMedCrossRef
20.
Croner RS, Peters A, Brueckl WM et al (2005) Microarray versus conventional prediction of lymph node metastasis in colorectal carcinoma. Cancer 104:395–404PubMedCrossRef
21.
Barrier A, Boelle PY, Roser F et al (2006) Stage II colon cancer prognosis prediction by tumor gene expression profiling. J Clin Oncol 24:4685–4691PubMedCrossRef
22.
Barrier A, Roser F, Boelle PY et al (2007) Prognosis of stage II colon cancer by non-neoplastic mucosa gene expression profiling. Oncogene 26:2642–2648PubMedCrossRef
23.
Lin YH, Friederichs J, Black MA et al (2007) Multiple gene expression classifiers from different array platforms predict poor prognosis of colorectal cancer. Clin Cancer Res 13:498–507PubMedCrossRef
24.
Vendrell E, Ribas M, Valls J et al (2007) Genomic and transcriptomic prognostic factors in R0 Dukes B and C colorectal cancer patients. Int J Oncol 30:1099–1107PubMed
25.
O’Connell MJ, Lavery I, Yothers G et al (2010) Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol 28:3937–3944PubMedCrossRef
26.
Gray RG, Quirke P, Handley K et al (2011) Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol 29:4611–4619PubMedCrossRef
27.
Glas AM, Roepman P, Salazar R et al (2009) Development and validation of a robust prognostic and predictive signature for colorectal cancer (CRC) patients. ASCO Meet Abstr 27:4036
28.
Salazar R, Roepman P, Capella G et al (2011) Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol 29:17–24PubMedCrossRef
29.
Rosenberg R, Maak M, Simon I et al Independent validation of a prognostic genomic profile (ColoPrint) for stage II colon cancer (CC) patients. ASCO Meeting Abstracts 29:358
30.
Kennedy RD, Bylesjo M, Kerr P et al (2011) Development and independent validation of a prognostic assay for stage ii colon cancer using formalin-fixed paraffin-embedded tissue. J Clin Oncol 29:4620–4626PubMedCrossRef
31.
Roth AD, Tejpar S, Delorenzi M et al (2010) Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 28:466–474PubMedCrossRef
32.
Van Cutsem E, Kohne CH, Hitre E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417PubMedCrossRef
33.
Van Cutsem E, Kohne CH, Lang I et al (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29:2011–2019PubMedCrossRef
34.
Bokemeyer C, Bondarenko I, Hartmann JT et al (2011) Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 22:1535–1546PubMedCrossRef
35.
Bokemeyer C, Bondarenko I, Makhson A et al (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663–671PubMedCrossRef
36.
Folprecht G, Gruenberger T, Bechstein WO et al (2010) Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11:38–47PubMedCrossRef
37.
Maughan TS, Adams RA, Smith CG et al (2011) Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 377:2103–2114PubMedCrossRef
38.
De Roock W, Claes B, Bernasconi D et al (2010) Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11:753–762PubMedCrossRef
39.
De Roock W, Jonker DJ, Di Nicolantonio F et al (2010) Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304:1812–1820PubMedCrossRef
40.
Douillard JY, Siena S, Cassidy J et al (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28:4697–4705PubMedCrossRef
41.
Douillard J, Siena S, Cassidy J et al (2011) Final results from PRIME: Randomized phase III study of panitumumab (pmab) with FOLFOX4 for first line metastatic colorectal cancer (mCRC). ASCO Meet Abstr 29:3510
42.
Knijn N, Mekenkamp LJ, Klomp M et al (2011) KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer 104:1020–1026PubMedCrossRef
43.
Richman SD, Seymour MT, Chambers P et al (2009) KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 27:5931–5937PubMedCrossRef
44.
Khambata-Ford S, Garrett CR, Meropol NJ et al (2007) Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25:3230–3237PubMedCrossRef
45.
Spindler KL, Andersen RF, Jensen LH et al (2010) EGF61A>G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer. Ann Oncol 21:535–539PubMedCrossRef
46.
Moroni M, Veronese S, Benvenuti S et al (2005) Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6:279–286PubMedCrossRef
47.
Laurent-Puig P, Cayre A, Manceau G et al (2009) Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 27:5924–5930PubMedCrossRef
48.
Negri FV, Bozzetti C, Lagrasta CA et al (2010) PTEN status in advanced colorectal cancer treated with cetuximab. Br J Cancer 102:162–164PubMedCrossRef
49.
(2009) Libro Blanco de la Anatomía Patológica en España. Recursos, calidad e impacto de la Patología en España., 2nd edn. ISBN 13:978-84-692-1562-3
50.
Bosman FT, Organization WH, Cancer IAfRo (2010) WHO classification of tumours of the digestive system. In: Fred T, Bosman et al. (eds) 4th edn. IARC Press, Lyon
51.
Balschun K, Haag J, Wenke AK et al (2011) KRAS, NRAS, PIK3CA exon 20, and BRAF genotypes in synchronous and metachronous primary colorectal cancers diagnostic and therapeutic implications. J Mol Diagn 13:436–445PubMedCrossRef
52.
Bouchahda M, Karaboue A, Saffroy R et al (2010) Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis. Cancer Chemother Pharmacol 66:605–609PubMedCrossRef
53.
Italiano A, Hostein I, Soubeyran I et al (2010) KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications. Ann Surg Oncol 17:1429–1434PubMedCrossRef
54.
Mariani P, Lae M, Degeorges A et al (2010) Concordant analysis of KRAS status in primary colon carcinoma and matched metastasis. Anticancer Res 30:4229–4235PubMed
55.
Hernández-Losa J, Sanz J, Landolfi S et al (2012) Recomendaciones para la determinación de mutaciones de K-RAS en cáncer de colon. Rev Esp Patol (In press)
56.
Goldstein NS, Armin M (2001) Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 92:1331–1346PubMedCrossRef
57.
Hemmings C, Broomfield A, Bean E et al (2009) Immunohistochemical expression of EGFR in colorectal carcinoma correlates with high but not low level gene amplification, as demonstrated by CISH. Pathology 41:356–360PubMedCrossRef
58.
Rego RL, Foster NR, Smyrk TC et al (2010) Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status. Br J Cancer 102:165–172PubMedCrossRef
59.
de Castro-Carpeno J, Belda-Iniesta C, Casado Saenz E et al (2008) EGFR and colon cancer: a clinical view. Clin Transl Oncol 10:6–13PubMedCrossRef
60.
Frattini M, Saletti P, Romagnani E et al (2007) PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 97:1139–1145PubMedCrossRef
61.
Jhawer M, Goel S, Wilson AJ et al (2008) PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 68:1953–1961PubMedCrossRef
62.
Perrone F, Lampis A, Orsenigo M et al (2009) PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 20:84–90PubMedCrossRef
63.
Jang KS, Song YS, Jang SH et al (2010) Clinicopathological significance of nuclear PTEN expression in colorectal adenocarcinoma. Histopathology 56:229–239PubMedCrossRef
64.
Hsu CP, Kao TY, Chang WL et al (2011) Clinical significance of tumor suppressor PTEN in colorectal carcinoma. Eur J Surg Oncol 37:140–147PubMedCrossRef
65.
Sangale Z, Prass C, Carlson A et al (2011) A robust immunohistochemical assay for detecting PTEN expression in human tumors. Appl Immunohistochem Mol Morphol 19:173–183PubMedCrossRef
66.
Mao C, Yang ZY, Hu XF et al (2011) PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Ann Oncol 23(6):1518–1525
67.
Shtilbans V, Wu M, Burstein DE (2008) Current overview of the role of Akt in cancer studies via applied immunohistochemistry. Ann Diagn Pathol 12:153–160PubMedCrossRef
68.
Washington MK, Berlin J, Branton P et al (2009) Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. Arch Pathol Lab Med 133:1539–1551PubMed
69.
Sanjuan X, Salas A, Lloreta J et al (2010) Colorectal Cancer OncoGuia: surgical pathology report guidelines. Clin Transl Oncol 12:211–213PubMedCrossRef
70.
Sobin LH GMaWC (2009) TNM classification of malignant tumours. 7th edn. Wiley, New York
71.
Metadata
Title
Guidelines for biomarker testing in colorectal carcinoma (CRC): a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM)
Authors
Pilar García-Alfonso
Ramón Salazar
Jesús García-Foncillas
Eva Musulén
Rocío García-Carbonero
Artemio Payá
Pedro Pérez-Segura
Santiago Ramón y Cajal
Samuel Navarro
Publication date
01-10-2012
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 10/2012
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-012-0856-5

Other articles of this Issue 10/2012

Clinical and Translational Oncology 10/2012 Go to the issue

Research Article

Murine bone marrow stromal cells pulsed with homologous tumor-derived exosomes inhibit proliferation of liver cancer cells

Research Article

Defects in mTR stability and telomerase activity produced by the Dkc1 A353V mutation in dyskeratosis congenita are rescued by a peptide from the dyskerin TruB domain

Editorial

Cost-effectiveness, cancer burden and financial crisis: a perfect storm

Educational Series – Red Series*

Surveillance of resected non-small cell lung cancer

Research Article

The SGBS cell strain as a model for the in vitro study of obesity and cancer

Research Article

Induced apoptosis in human prostate cancer cells by blocking of vascular endothelial growth factor by siRNA
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits